▶ 調査レポート

腎臓がんの治療薬・診断の世界市場:治療薬別(パクリタキセルアルブミン(アブラキサン)、エベロリムス(アフィニトール)、塩酸エルロチニブ(タルセバ)、フルオロウラシル、塩酸ゲムシタビン、塩酸イリノテカン、マイトマイシンC、リンゴ酸スニチニブ(スーテント)、その他)、診断別(画像検査、生検、内視鏡検査、その他)、地域別分析

• 英文タイトル:Global Pancreatic Cancer Therapeutics & Diagnostics Market - Segmented by Therapeutics, Diagnostics, and Geography - Growth, Trends, and Forecast (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。腎臓がんの治療薬・診断の世界市場:治療薬別(パクリタキセルアルブミン(アブラキサン)、エベロリムス(アフィニトール)、塩酸エルロチニブ(タルセバ)、フルオロウラシル、塩酸ゲムシタビン、塩酸イリノテカン、マイトマイシンC、リンゴ酸スニチニブ(スーテント)、その他)、診断別(画像検査、生検、内視鏡検査、その他)、地域別分析 / Global Pancreatic Cancer Therapeutics & Diagnostics Market - Segmented by Therapeutics, Diagnostics, and Geography - Growth, Trends, and Forecast (2018 - 2023) / B-MOR-08436資料のイメージです。• レポートコード:B-MOR-08436
• 出版社/出版日:Mordor Intelligence / 2018年5月1日
• レポート形態:英文、PDF、112ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:医療・製薬
• 販売価格(消費税別)
  Single User(1名様用)¥450,500 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥477,000 (USD4,500)▷ お問い合わせ
  Corporate User¥927,500 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、腎臓がんの治療薬・診断の世界市場について調べ、腎臓がんの治療薬・診断の世界規模、市場動向、市場環境、治療薬別(パクリタキセルアルブミン(アブラキサン)、エベロリムス(アフィニトール)、塩酸エルロチニブ(タルセバ)、フルオロウラシル、塩酸ゲムシタビン、塩酸イリノテカン、マイトマイシンC、リンゴ酸スニチニブ(スーテント)、その他)分析、診断別(画像検査、生検、内視鏡検査、その他)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・腎臓がんの治療薬・診断の世界市場インサイト
・腎臓がんの治療薬・診断の世界市場環境
・腎臓がんの治療薬・診断の世界市場動向
・腎臓がんの治療薬・診断の世界市場規模
・腎臓がんの治療薬・診断の世界市場規模:治療薬別(パクリタキセルアルブミン(アブラキサン)、エベロリムス(アフィニトール)、塩酸エルロチニブ(タルセバ)、フルオロウラシル、塩酸ゲムシタビン、塩酸イリノテカン、マイトマイシンC、リンゴ酸スニチニブ(スーテント)、その他)
・腎臓がんの治療薬・診断の世界市場規模:診断別(画像検査、生検、内視鏡検査、その他)
・腎臓がんの治療薬・診断の世界市場:地域別市場規模・分析
・腎臓がんの治療薬・診断の北米市場規模・予測
・腎臓がんの治療薬・診断のアメリカ市場規模・予測
・腎臓がんの治療薬・診断のヨーロッパ市場規模・予測
・腎臓がんの治療薬・診断のアジア市場規模・予測
・腎臓がんの治療薬・診断の日本市場規模・予測
・腎臓がんの治療薬・診断の中国市場規模・予測
・腎臓がんの治療薬・診断のインド市場規模・予測
・腎臓がんの治療薬・診断の韓国市場規模・予測
・関連企業情報・競争状況

Pancreatic cancer occurs when there is an uncontrollable growth of cells in the pancreas. Pancreatic cancer is categorized as exocrine and endocrine, based on the cells affected by cancer. Exocrine cells in pancreas create pancreatic enzymes. When cancer manifests in these cells, it is referred to as exocrine pancreatic cancer. Endocrine cells are a small cluster of cells and also called ‘islets of Langerhans’. These cells create hormones, such as insulin and glucagon, releasing them into the blood flow. Cancer in these cells is called endocrine pancreatic cancer. The global pancreatic cancer therapeutics & diagnostics market is expected to witness a CAGR 5.6% during the forecast period, 2018-2023.
Increasing Incidence and Prevalence of Pancreatic Cancer

Pancreatic cancer is the 12th-most common cancer in the world. The estimated five-year prevalence of people living with pancreatic cancer is 4.1 per 100,000, globally. This cancer is almost always fatal, and is the seventh most common cause of death from cancer. Pancreatic cancer is closely related to body fat and high BMI, thereby being more prevalent in developed countries. A report by the Centers for Disease Control and Prevention (CDC) estimated that pancreatic cancer resulted in the death of about 330,000 people in 2012 in the United States, which was around 4% of all deaths in the country. Estimates of the American Cancer Society suggested that in the United States alone, nearly 53,070 new cases of pancreatic cancer were recorded in 2016 and 41,780 deaths in the country were attributed to the same. In Europe, nearly 104,000 new cases of pancreatic cancer were estimated to be diagnosed in 2012. The extensive threat of pancreatic cancer is a major opportunity for companies to capitalize on the market through the expansion of product portfolios and market penetration. The high patient pool and increasing trends of the same are expected to propel the growth of the market.
Chronic nature of diseases leads to consistent demand for drugs, advancements in molecular biology, development of drugs and diagnostic technology, and emphasis on early diagnosis, which are driving the market growth.

Drug Toxicity or Drug Side Effects

Several drugs prescribed for the treatment of pancreatic cancer are associated with adverse effects, ranging from mild to severe. There are many lists of drugs, like Tarceva, a drug which is used to treat pancreatic cancer, can lead to pregnancy-related problems, harm the fetus, and can also cause complete failure of liver and kidney functioning. People who have used Afinitor as a treatment regimen for pancreatic cancer have reported loss of appetite, multiple infections, hypercholesterolemia, headache, pneumonitis, stomatitis, diarrhoea, asthenia, weight loss, etc. The possibility of multiple side effects, with a few that can even cause death, results in the reluctance in prescribing drugs to patients. The usage of drugs that cause side effects acts as a major restraint to the global pancreatic cancer drugs market.
Other factors restraining the market are drugs losing patent exclusivity, high costs associated with diagnosis and treatments, and stringent regulatory guidelines.

United States to have the Highest Market Share

In the United States, the average lifetime risk of pancreatic cancer for both men and women is about 1 in 65 (1.5%). Pancreatic cancer accounts for about 3% of all cancers in the United States and about 7% of cancer deaths. The Pancreatic Cancer Action Network predicts pancreatic cancer to become the second leading cause of cancer-related deaths in the United States, by 2020. With promising drugs in the pipeline, the US pancreatic cancer therapeutics & diagnostics market is expected to witness lucrative growth during the forecast period. The high healthcare spending and state-of-the-art healthcare facilities in the United States are expected to promote the growth of the market, indirectly. The country is also a hub for high-end R&D activities, which are anticipated to have a positive impact on novel product developments and clinical trials.

Key Developments in the Market

• October 2017 – Amgen and CytomX Therapeutics announced a strategic collaboration in immuno-oncology.
• September 2017 – FDA approved Amgen and Allergan’s MVASI™ (bevacizumab-awwb) for the treatment of five types of cancer.
• May 2017 – NantKwest, NantCell was expected to test NANT vaccine in Phase 1/2 trial for pancreatic cancer patients.

Major players – AMGEN INC., BECKMAN COULTER, BIORAD LABORATORIES INC., CELGENE CORPORATION, CLOVIS ONCOLOGY INC., ELI LILLY, F. HOFFMANN-LA ROCHE, GENENTECH INC., IPSEN PHARMACEUTICALS, NOVARTIS INTERNATIONAL AG, AND PFIZER, amongst others

Reasons to Purchase this Report

• Market analysis for the global pancreatic cancer therapeutics & diagnostics market, with region-specific assessments and competition analysis on a global and regional scale
• Analyzing various perspectives of the industry with the help of Porter’s five forces analysis
• The treatment type that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our representative, who will ensure that you get a report that suits your needs.

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Incidence and Prevalence of Pancreatic Cancer
6.1.2 Chronic Nature of Diseases Leads to Consistent Demand for Drugs
6.1.3 Advancements in Molecular Biology, Development of Drugs, and Diagnostic Technology
6.1.4 Emphasis on Early Diagnosis
6.2 Market Restraints
6.2.1 Drug Toxicity and Side Effects
6.2.2 Drugs Losing Patent Exclusivity
6.2.3 High Costs Associated with Diagnosis and Treatments
6.2.4 Stringent Regularly Guidelines
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Therapeutic
7.1.1 Paclitaxel Albumin (Abraxane)
7.1.2 Everolimus (Afinitor)
7.1.3 Erlotinib Hydrochloride (Tarceva)
7.1.4 Fluorouracil
7.1.5 Gemcitabine Hydrochloride
7.1.6 Irinotecan Hydrochloride
7.1.7 Mitomycin C
7.1.8 Sunitinib Malate (Sutent)
7.1.9 Others
7.2 By Diagnostic
7.2.1 Imaging
7.2.2 Biopsy
7.2.3 Endoscopy
7.2.4 Others
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC Countries
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest Of South America
8. Competitive Landscape
8.1 Mergers & Acquisitions Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Amgen Inc.
9.2 Beckman Coulter
9.3 Biorad Laboratories Inc.
9.4 Celgene Corporation
9.5 Clovis Oncology Inc.
9.6 Eli Lilly
9.7 F. Hoffmann-La Roche
9.8 Genentech Inc.
9.9 Ipsen Pharmaceuticals
9.10 Novartis International AG
9.11 Pfizer
9.12 List not Exhaustive
10. Future of the Market